autologous stem-cell transplantationHodgkin's lymphomaNorton-Simon hypothesisrelapsesequential high-dose chemotherapyNature Clinical Practice Oncology will deliver timely interpretations of key research developments, translating the latest findings into clinical practice. Our Editor-in-Chief and international ...
Letizia Galgano and Daphna Hutt 2 Abstract The HSCT (haematopoietic stem cell transplant) is a particular treatment for many haematological and non-haematological diseases. Broadly, there are three different categories of transplantation, autologous, allogeneic and syn- geneic, which can be ...
The HSCT (haematopoietic stem cell transplant) is a particular treatment for many haematological and non-haematological diseases. Broadly, there are three different categories of transplantation, autologous, allogeneic and syngeneic, which can be applied to most disease scenarios. Haematopoietic stem cells ...
A stem cell transplant is a procedure in which a patient receives healthy stem cells to replace damaged stem cells. The stem cells may come from the patient's own body (autologous) or from a donor (allogeneic). Before the transplant, the patient receives high doses of chemotherapy and somet...
18: Does Antinuclear Antibody (ANA) Have a Role in Lymphoma Patients?doi:10.1097/01.tp.0000581284.37557.93Kumar, MahendraPrakash, GauravMinz, Ranjana WMalhotra, PankajBal, AmanjitTransplantation
your doctor will diagnose you with Hodgkin lymphoma. There are two main types: classical and nodular lymphocyte predominant. Cancer treatments such as chemotherapy can cure many people with this type of lymphoma. And if it comes back, chemo combined with stem cell transplants works well to wipe...
Can a stem cell transplant cure multiple myeloma? How long does it take for liver cancer to metastasize? How long can a person live with secondary bone cancer?Explore our homework questions and answers library Search Browse Browse by subject Ask a Homework Question Tutors available × Our tut...
Impact of Pre-transplant Rituximab on Survival after Autologous Hematopoietic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma = .008) and overall survival (OS; 57% vs 45%; = .006) at 3 years. Platelet and neutrophil engraftment were not affected by exposure to rituximab. Nonrelaps...
These patients had a high risk of post-CAR relapse without further treatment with a consolidative hematopoietic stem cell transplant [11]. For patients receiving CARs containing the 4-1BB co-stimulatory signaling domain (Figure 1), persistence of CAR T cells could be observed for months to ...
influenced only controls regarding hospitalizations and emergency room visits. Differences were not significant on deaths (intervention 4.2% vs. control 9.5%;p= 0.4) (4) Conclusions: the mHeart strategy significantly reduced the occurrence of the studied post-transplant complications and the need for ...